2019
Epigenetic therapy combinations in acute myeloid leukemia: what are the options?
Bewersdorf JP, Shallis R, Stahl M, Zeidan AM. Epigenetic therapy combinations in acute myeloid leukemia: what are the options? Therapeutic Advances In Hematology 2019, 10: 2040620718816698. PMID: 30719265, PMCID: PMC6348528, DOI: 10.1177/2040620718816698.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAcute myeloid leukemiaCombination therapyTherapy combinationsMyeloid leukemiaEpigenetic therapyAdvanced clinical testingTherapeutic optionsClinical trialsConventional chemotherapyClinical dataPreclinical studiesAML pathogenesisClinical practiceSingle agentClinical testingTherapyLeukemic pathogenesisDriver mutationsDNA methylationHistone methylation inhibitorPathogenesisLeukemiaDehydrogenase inhibitorEpigenetic alterationsActual DNA sequence
2018
The genetic and molecular pathogenesis of myelodysplastic syndromes
Shallis RM, Ahmad R, Zeidan AM. The genetic and molecular pathogenesis of myelodysplastic syndromes. European Journal Of Haematology 2018, 101: 260-271. PMID: 29742289, DOI: 10.1111/ejh.13092.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMolecular pathogenesisGene expression profilingSignal transduction elementsDevelopment of MDSHigh-throughput techniquesCohesin proteinsMyelodysplastic syndromeRNA splicingDNA methylationTranscription factorsDNA repairMolecular basisExpression profilingMalignant myeloid disordersBone marrow microenvironmentGenetic materialClonal architectureSuch mutationsTransduction elementsInflammatory bone marrow microenvironmentMarrow microenvironmentImportant substrateGenetic mutationsDiverse groupPathophysiology of MDS